EUVIMEDEUVIMED entdecken
Crossref

AX-35 Targets the Cytochrome bc1 Complex in Mycobacterium abscessus and Reveals a Novel Resistance Mechanism

Andréanne Lupien iD, Thomas Dessureault, Caroline Shi-Yan Foo, Maryline Kienle, Anthony Vocat, Andrej Benjak, Iain Roe, Karl-Heinz Altmann iD, Stewart T Cole, Marcel A Behr

ACS Infectious Diseases · 09.10.2026 · 12 (10) · 3362-3372

DOI: 10.1021/acsinfecdis.6c00313 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 28.09.2026. Verfasst von Andréanne Lupien und 9 weiteren Autor:innen. Beteiligte Einrichtung: McGill University Faculty of Medicine and Health Sciences, Medicine, 1001 boul Decarie, Montreal, QuebecH4A 3J1, Canada. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Electron Transport Complex III, Drug Resistance, Bacterial, Antitubercular Agents. Die Arbeit nennt 44 Literaturangaben. Gefördert von: FP7 Health, Canada Research Chairs, Canadian Institutes of Health Research (CIHR).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In patients with cystic fibrosis, nontuberculous mycobacteria are opportunistic, intracellular and extracellular pulmonary pathogens that contribute to deterioration of lung function and, ultimately, morbidity from respiratory failure. Among nontuberculous mycobacterial respiratory pathogens, members of the Mycobacterium abscessus complex pose additional treatment complications as they are notoriously drug-resistant. As part of our routine screening against mycobacterial species, one of the lead antituberculosis compounds, the cytochrome bc1 inhibitor AX-35, was found to be active against isolates from the Mycobacterium abscessus complex in vitro (MIC ≤ 15 μg/mL) and ex vivo in infected macrophages. Isolation and characterization of AX-35-resistant mutants in M. abscessus ATCC 19977 (MIC AX-35 > 100 μg/mL) revealed the presence of a chimeric gene resulting from the recombination of 737 bps of MAB_2467 into MAB_1966c. In M. abscessus, both genes encode for the b subunit of the cytochrome bc1 oxidase, also known as QcrB. Further analysis, comprising gene inactivation, ATP-depletion assays, AlphaFold3-based structural modeling, and molecular docking, suggested that the product of MAB_1966c is the target of AX-35. Interestingly, transcriptomic analysis of M. abscessus exposed to AX-35 revealed that the compound induced expression of MAB_2467 and the alternate terminal oxidase, cytochrome bd. In M. tuberculosis, in the absence of the cytochrome bd oxidase, QcrB inhibitors, including AX-35, are bactericidal. However, in M. abscessus, AX-35 had bacteriostatic activity. These results suggested that, in the presence of AX-35, MAB_2467 may compensate for the absence of the cytochrome bd oxidase and that M. abscessus ATCC 19977 genome encodes two QcrB paralogs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium abscessusElectron Transport Complex IIIDrug Resistance, BacterialAntitubercular AgentsHumansMicrobial Sensitivity TestsMacrophagesBacterial ProteinsMycobacterium Infections, NontuberculousMolecular Docking Simulation

Stichwörter der Autor:innen

AX-35Mycobacterium abscessusQcrBchimeric geneoxidative phosphorylation

Substanzen

Electron Transport Complex IIIAntitubercular AgentsBacterial Proteins

Autor:innen und Institutionen

  • McGill University Faculty of Medicine and Health Sciences, Medicine, 1001 boul Decarie, Montreal, QuebecH4A 3J1, Canada.
  • Research Institute of the McGill University Health Centre, Infectious Diseases and Immunity in Global Health Program , 1001 boul Decarie, Montreal, QuebecH4A3J1, Canada.
  • McGill University Faculty of Medicine and Health Sciences, Microbiology and Immunology, 3775 Rue University Room 511, Montreal, QuebecH3A0G4, Canada.
  • Global Health Institute, Ecole Polytechnique Fédérale de Lausanne, Lausanne1015, Switzerland.
  • ETH Zurich Institute of Pharmaceutical Sciences , Department of Chemistry and Applied Biosciences, Vladimir-Prelog-Weg 4, Zürich, Zürich8093, Switzerland.

ORCID-Profile: Andréanne Lupien, Karl-Heinz Altmann

Förderung

  • FP7 Health
  • Canada Research Chairs
  • Canadian Institutes of Health Research (CIHR)

Zitieren

APA

Lupien, A., Dessureault, T., Foo, C. S., Kienle, M., Vocat, A., Benjak, A., Roe, I., Altmann, K. H., Cole, S. T., & Behr, M. A. (2026). AX-35 Targets the Cytochrome bc1 Complex in Mycobacterium abscessus and Reveals a Novel Resistance Mechanism. ACS Infectious Diseases, 12(10), 3362-3372. https://doi.org/10.1021/acsinfecdis.6c00313

Vancouver

Lupien A, Dessureault T, Foo CS, Kienle M, Vocat A, Benjak A, et al. AX-35 Targets the Cytochrome bc1 Complex in Mycobacterium abscessus and Reveals a Novel Resistance Mechanism. ACS Infectious Diseases. 2026;12(10):3362-3372. doi:10.1021/acsinfecdis.6c00313

BibTeX
@article{Lupien2026,
  author = {Lupien, Andréanne and Dessureault, Thomas and Foo, Caroline Shi-Yan and Kienle, Maryline and Vocat, Anthony and Benjak, Andrej and Roe, Iain and Altmann, Karl-Heinz and Cole, Stewart T and Behr, Marcel A},
  title = {AX-35 Targets the Cytochrome bc1 Complex in Mycobacterium abscessus and Reveals a Novel Resistance Mechanism},
  journal = {ACS Infectious Diseases},
  year = {2026},
  volume = {12},
  number = {10},
  pages = {3362--3372},
  doi = {10.1021/acsinfecdis.6c00313}
}
Kostenlos starten →